• The health and wellness industry has been growing in recent years amid increasing efforts to improve quality of life, as well as concerns about the rising costs of medical care
• The global hemp industry is expected to grow at a CAGR of 34 percent between now and 2025 as a subset of the wellness industry
• Texas-based Neutra Corp. is expanding into hemp cultivation and purified hemp extract products under a revenue-generating model that emboldens its strategy for building natural remedies to better the human body and the global environment
• A key part of the company’s strategy involves the recent acquisition of hemp-based health and nutritional product retail brand Vivis Corp. and an LOI to obtain J3 Holdings’ land, warehouse and cultivation license for growing and refining hemp

Neutra Corp. (OTCQB: NTRR) is a company intent on pursuing its interest in developing modern, healthy living solutions in a world that’s ever more focused on quality of life concerns and the rising costs of health care. Neutra Corp.’s initial focus was on bringing to market products derived from all natural and organic origins, as a nutraceutical firm developing natural remedies that promote the body’s ability to heal and maintain itself, when the company was founded in 2011.

The explosion of nutraceutical opportunities in the cannabis derivative market as societal attitudes and governmental regulations have undergone changes in recent years has led Neutra Corp. to pursue the possibility of monetizing early stage research and development efforts to constructively aid the human body and the global environment, scaling vertically with nutraceutical, food and environmental purification holdings.

“In 2019 we’re really looking at trying to figure out how to participate in the hemp-based CBD market,” CEO Sydney Jim said during a recent interview with NetworkNewsAudio (http://ibn.fm/yy7WS). “Our overall goal is to become a vertically integrated company from cultivation to manufacturing to formulation of products and then to distribution and retail sales.”

The wellness industry grew by 6.4 percent each year from 2015 to 2017, topping $4.2 trillion as a market growing nearly twice as fast as the global economy, according to a report issued last fall by The Global Wellness Institute (http://ibn.fm/s6lZR). The global hemp industry is forecast to grow as a segment of the health and wellness market with a CAGR of 34 percent between now and 2025, according to Research and Markets analysts, growing from $4.6 billion to $26.6 billion (http://ibn.fm/W9YOL).

As the global cannabis market continues to grow, it will have a constant need for developing technologies and products that increase business efficiencies in plant cultivation processes, the types of plants to be cultivated and consumption methods. Neutra Corp. is constantly combing the industry for the latest and greatest products to test, prove and bring to market, whether lighting resources, dosage devices, pesticide alternatives or plant nurturing elements, according to the company’s most recent quarterly statement issued September 23 (http://ibn.fm/teboZ).

As part of Neutra Corp.’s strategy for generating revenue, the company recently announced the tactical acquisition of emerging hemp-based health and nutritional product retail brand Vivis Corp. from Jim, who is also Vivis’ founder and CEO. All of Vivis’ CBD products are tested and certified by a third party to ensure their purity (http://ibn.fm/g8KeW).

Vivis has one product line that uses a 99 percent or higher grade of hemp-extracted crystalline CBD, and the company expects to soon launch a second brand with an 80 percent or higher grade of full-spectrum CBD extract.

The company intends to entrust the manufacturing of its products to a nutraceutical contractor to private label all of its products and sell them under Neutra Corp.’s unique brand, according to Neutra Corp.’s quarterly report. The company will continue seeking ways to fund its ventures as a natural part of operations, and it believes that its projects and initiatives will successfully come to provide cash flow that Neutra Corp. can use to finance future growth.

Neutra Corp. has also signed a letter of intent to acquire J3 Holdings, a company that has land, a warehouse and a license to cultivate and refine hemp that are expected to prove valuable additions to Neutra Corp’s stable.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• The consolidation of corporate pharmacy chains and constantly increasing competition are two of the main factors contributing to the problems facing independent and community pharmacies
• The pharmaceutical sector is incredibly lucrative, with large players such as Amazon also attempting to secure part of the market; as a result of such large developments, community pharmacies have been experiencing declining profits and margins
• Trxade Group is working to empower independent pharmacy owners by providing valuable support and information about affordable supplying options; access to real-time information gives small pharmacies the tools needed to compete against large industry players

Growing competition and the consolidation of corporate pharmacy chains are two of the biggest challenges that small and independent pharmacies have to overcome. Companies like Trxade Group Inc. (OTCQB: TRXD) are working on the development of technological solutions that will enable small industry players to remain competitive.

A number of pharmacy chains dominate the prescription drug market in the U.S. Statistics from 2018 suggest that the biggest industry player alone holds 24.2 percent of the market, followed by the second largest chain, which holds 17.5 percent (http://ibn.fm/nLdnb). Adding declining margins to the mix makes it very difficult for small community pharmacies to stay afloat.

One of the latest developments that has impacted the business of small pharmacies in the U.S. is the Amazon acquisition of PillPack (http://ibn.fm/2Qbnc). The deal was concluded in 2018, but the effect it’s having on the pharmaceutical market is only being amplified with the passage of time.

PillPack offers online sales, delivering most of the medications that consumers can get in brick-and-mortar pharmacies. Automatic refills and 24/7 customer support add to the convenience of the service and boost the threat that smaller industry players are facing.

All of these major developments are contributing to a trend that has been ongoing for several years. Since 2016, there has been a sustainable declining profits trend among independent pharmacies (http://ibn.fm/M9wU8). During that year alone, overall gross margins for prescription and non-prescription products were 22.1 percent, in comparison to 24 percent in 2010. As a result of such trends, the number of independent pharmacies has been steadily declining.

However, community pharmacies and small businesses do have an opportunity to fight back and ensure their economic survival. This is where Trxade Group, an integrated pharmaceutical services company that focuses on supporting independent and community-based pharmacies, comes in.

The company’s Trxade Exchange platform creates new and widens existing distribution channels for independent pharmacies. The service enables members of the platform to view manufacturer, wholesaler and buyer group prices. The real-time information makes it easy to access the most affordable supplies and improve overall margins.

As of September 2019, Trxade Exchange’s membership has reached 10,500 pharmacies out of the 24,000 independent entities operating in the U.S. Joining the platform makes it easier for smaller industry representatives to compete with the large retail chains that have solid, affordable supply agreements because they can buy in bulk.

Trxade Group is constantly working to empower small businesses. Apart from its Trxade Exchange platform, the company is developing additional products to maximize data analysis capabilities and inventory management.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• CIIX CEO Warren Wang reported that MicroCap Conference attendees showed interest in the company’s presentation
• In a MoneyTV interview, Wang expressed optimism about the long-range sales of CBD; CIIX will focus on the CBD cosmetics sector
• CIIX reported a 175 percent YOY sales increase for FY2019; industrial hemp and CBD liquor products showed sharp gains

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said in a MoneyTV interview with host Donald Baillargeon that he was pleased with the reaction to the company’s presentation at the MicroCap Conference, held recently at the Essex House in New York. The presentation was given by Alex Hamilton, CFO of CIIX subsidiary Biotech CBD Inc. (http://ibn.fm/P1TVf).

The conference was designed to bring together high-level institutional and retail investors with publicly held small- and micro-cap companies. Wang noted that he is optimistic about the long-term growth of CBD sales and said that, moving forward, the company plans to focus on cosmetics in the category. According to New Frontier Data, the U.S. hemp CBD market is expected to triple in value by 2022. Likewise, according to Hemp Industry Daily market projections, the national market for hemp-derived CBD is expected to balloon to $7 billion by 2023 (http://ibn.fm/1uxPo).

In addition, CIIX reported sharp gains of 175 percent year-over-year for its FY2019, ended in May 2019. That gain was generated by FY2019 sales of $6,476,442, as compared to $2,353,331 in FY2018, according to its 10-K SEC filing (http://ibn.fm/LIZnq). The increase was driven by industrial-hemp and CBD-liquor product sales of $4,189,935 in FY2019, as compared to $378,984 in FY2018 (http://ibn.fm/PO4wS). Investor relations, a core business for the company, generated gains as well, with sales totaling $1,336,402 in FY2019, as compared to $968,282 the prior year.

Earlier, Wang projected that CIIX sales will reach $11 million to $12 million in FY2020 – the 12 months ending in May 2020. That projection was made during a wide-ranging interview on the Redchip Money Report with host Dave Gentry, broadcast on YouTube. The company has long been reaching a Chinese-speaking audience in the United States and Canada with investment information on issues ranging from cryptocurrency to CBD.

In the same interview, Wang also noted that investors should know that CIIX is seeking to expand its future business. “We are going to do some merger/acquisition to expand our business in the Asian region,” he told the host.

CIIX is a diverse company driven not only by educational services but also by sales of cosmetics, hemp wine and CBD. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers
• Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols
• Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer
• The company recently announced that Daniel J. Shea has joined the team as chief financial officer and senior vice president, in anticipation of growth

Pressure BioSciences Inc.’s (OTCQB: PBIO) novel and powerful Pressure Cycling Technology (PCT) platform has performed excellently during the processing of preserved (FFPE) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers, as indicated by two recently published scientific articles about the technology’s performance.

Independent teams of scientists from China and Australia led the research, and their data suggest that the Pressure BioSciences technology could potentially be used in the clinical diagnostic process based on the cancer biomarkers, as the company noted in a press release (http://ibn.fm/DfmC7). Chinese researchers purchased their first two PCT platforms in 2017 and subsequently purchased four additional systems. In Australia, the PCT platform has been in use since 2016.

Because of the large amount of support data on preserved tissue samples like the ones used in the Chinese and the Australian research studies, such samples are considered invaluable for the retrospective study of disease progression and response to therapy. The use of such samples could speed up the discovery of new therapies and preventative strategies, but, up until now, the successful extraction of high-quality biomolecules from FFPE samples has been difficult to accomplish, at best.

According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be key to the discovery of new cancer biomarkers, development of new cancer diagnostics, and release of new treatments and prevention measures, Schumacher concluded.

“We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market,” Pressure BioSciences’ director of marketing and sales Roxana McCloskey added.

The global cancer biomarker market is anticipated to reach more than $157 billion by 2022. This is just one of the multiple important applications of Pressure BioSciences’ innovative pressure-based technology platform.

To prepare for the anticipated growth in the years to come, Pressure BioSciences announced a strategic team addition on September 17, 2019. According to an official company announcement, Daniel J. Shea has joined the team as chief financial officer and senior vice president (http://ibn.fm/3rLyE).

Shea has over 30 years of experience in leading and advising financial organizations. Since the beginning of 2017, Shea has operated a CPA advisory firm called Woodcliff Advisors LLC, which provides counsel to boards, CFOs and members of senior management teams.

“PBIO’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years,” Shea said, commenting on the appointment.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• The Green Organic Dutchman produces high-quality, organic cannabis for the medicinal and recreational adult use markets from purpose-built, state-of-the-art facilities
• The company has confirmed higher demand for premium organic cannabis
• TGOD has also announced positive results from its pharmacokinetic study of innovative cannabinoid technology

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is an international, premium organic cannabis company based in Mississauga, Ontario. The company produces high-quality, organic medical and recreational adult use cannabis using organic craft growing principles. TGOD plans on commercializing organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products, and results from a recent study have given support to that move. Additionally, TGOD was able to report strong demand for its premium organic cannabis following its Ontario launch and fast-tracked shipments.

Following its Ontario launch and fast-tracked shipments, TGOD reported that there is a strong demand for its premium organic cannabis (http://ibn.fm/wOW3S). After the August launch, initial demand surpassed expectations. The company’s high-THC (tetrahydrocannabinol) signature strain, Unite Organic, performed well both online and at dispensaries, resulting in a second order from the Ontario Cannabis Store – earlier than initially anticipated. The strong launch marks TGOD’s successful entrance into the Canadian recreational market.

While cannabis companies abound, TGOD continues to impress with its organic emphasis and the overall quality of its products. TGOD’s cannabis is grown in its proprietary living soil, in accordance with all-natural principles. Moreover, its growing process is certified organic by Pro-Cert and ECOCERT, two top organic certification bodies. Of note is the fact that, according to a 2019 study conducted by Hill & Knowlton, more than 50 percent of recreational consumers intending to purchase cannabis stated that it is important that their cannabis be organic, and over 60 percent of medical patients prefer organic cannabis. As one of the few certified-organic companies in Canada, these numbers give TGOD an edge in the market.

While TGOD’s premium cannabis products are thriving, the company also plans on introducing organic CBD-dissolvables to the market. In line with that goal, TGOD and Caliper Foods recently reported positive results from a pharmacokinetic study of proprietary, water-soluble cannabinoid technology (http://ibn.fm/JdgjH). The two companies revealed the results of a preliminary human pharmacokinetic (PK) study of Caliper CBD, Caliper Foods’ proprietary tasteless, odorless, water-soluble powder, which can be added to almost any food or beverage. Caliper Foods is a best-in-class provider of water-soluble cannabinoid products.

In the study, half of the participants were administered 30 milligrams of Caliper Foods’ water-soluble CBD powder in eight ounces of water; the other half received 30 milligrams of CBD dispersed in MCT oil. Early data shows that the group that received Caliper CBD demonstrated speedier onset within 15 minutes, with higher concentrations attained at 15 minutes versus the maximum concentration attained at 45 minutes with the CBD-in-oil formulation, and a 4.5-fold higher observed total bioavailability.

“We are thrilled with the results of this preliminary PK study, which demonstrate the consistency and precision of Caliper Foods’ proven proprietary technology, which is already available in Colorado and which TGOD will commercialize in Canada,” TGOD Chief Science Officer Dr. Rav Kumar stated in a news release (http://ibn.fm/J5bPQ). “Based on this early data, Caliper CBD provides a higher and faster absorption level when compared with CBD-infused oil, which opens a number of possibilities for both the medical and adult-use markets.”

With its proven management team and state-of-the-art facilities, TGOD continues to focus on providing a slate of premium consumer-preferred products. The company offers investors potential return on investment as it looks to grow via strategic international opportunities. TGOD’s hybrid facilities represent important advantages over indoor and outdoor greenhouses and set the stage for lower capex and greater profits.

TGOD’s operational emphasis is on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The company’s strategy is to grow organically and at low costs, resulting in a product that demands a premium in the marketplace, thereby increasing the company’s margins.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Earth Science Tech has launched a new sales division focused on CBD, led by Industry-veteran Erika Franck
• ETST’s portfolio is positioned in the dually lucrative biotechnology and cannabis/cannabidiol industries
• Biotechnology currently represents the largest segment of the growing legal cannabis market

Earth Science Tech Inc. (OTCQB: ETST) recently launched a new sales unit to further strengthen its position in the CBD marketplace for medical and pharmaceutical products. Erika Franck, who has previously served as the company’s clinical and therapeutics sales director, will be heading the division. ETST made this move in accordance with the growing use of CBD in the licensed medical fields and alternate medicinal streams.

The company, under the leadership of Franck, will target medical experts and specialists, suppliers, acupuncturists, chiropractors, practitioners of holistic wellness and alternative therapies, and veterinarians. With the appointment of Franck, the company receives her sound knowledge and experience in the pharmaceutical and orthopedics industry.

“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck stated in a news release (http://ibn.fm/Q84nZ). “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s continued growth as we achieve this mission.”

Earth Science Tech is well-positioned as a biotechnology company which focuses on the research and development of CBD, pharmaceuticals and medical device products. The company’s pure CBD oil is manufactured using CO2 liquid extraction processes; ETST prides itself on offering the finest quality pure CBD oil on the market.

The biotechnology segment of the cannabis industry consists of pharmaceutical firms focused on the research and development behind new drugs and products that utilize cannabinoids, which are the active compounds within cannabis. Currently the largest sector in the legal cannabis market, it is expected to see further growth as more entities around the world continue researching cannabinoids (http://ibn.fm/icNh9). This trend is encouraging for biotechnology companies like Florida-based ETST.

ETST projects a robust portfolio through its two wholly owned subsidiaries, which are focused on the research and production of cutting-edge industrial hemp and cannabis/cannabidiol (CBD) products to take advantage of the potential seen in the burgeoining cannabis industry.

ETST subsidiary Earth Science Pharma Inc. is engaged in the production of noninvasive economical diagnostic testing tools, medical devices and vaccines for sexually transmitted infections and/or diseases. Their first STI home detection kit using a modified panty liner (MSN-2), named Hygee, is a revolutionary product that can be used for chlamydia testing by women from their homes. The MSN-2 technology is further being utilized to screen for other STIs such as gonorrhea and thichomoniasis, and it holds disruptive potential in the women’s health sector.

Cannabis Therapeutics Inc., another of ETST’s subsidiaries, was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis/cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• SHRG works to elevate home-based entrepreneurs through its support of direct-selling programs
• The company’s Elepreneurs LLC is a wholly owned subsidiary
• SHRG utilizes a proprietary Blue Ocean Strategy and is concentrating on international expansion

Sharing Services Global Corporation (OTCQB: SHRG) is a diversified holding company that owns, operates or controls an interest in an array of companies specializing in the direct-selling industry. Based in Plano, Texas, SHRG works to elevate home-based entrepreneurs via the support of direct-selling programs.

SHRG’s emphasis is on reshaping how modern entrepreneurs succeed in the direct-selling industry. With that in mind, the company created and follows its own Blue Ocean Strategy. The strategy comprises three aspects: elevating home-based entrepreneurs, generating organic growth and creating independent business leaders.

More specifically, SHRG is growing a global network of home-based business owners called Elepreneurs (Elevated Entrepreneurs) to market and share collective products and services. In addition, SHRG is fostering 100 percent organic growth using its extensive and growing direct-selling channel. Furthermore, the company concentrates on providing mentorship and support to attract and develop an increasing number of successful independent business leaders (http://ibn.fm/gppvw). Evidence of the success of that strategy is the fact that SHRG has grown by thousands of independent representatives in the last several months.

For its independent representatives, SHRG provides business-development programs via live seminars and training events, classes, boot camps and workshops. Each of these are developed by Elepreneurs and conducted by the company’s team of experienced entrepreneurs. In addition, the company offers attractive compensation and rewards programs.

These initiatives all help SHRG’s Elepreneurs succeed in the thriving global direct-selling market, which increased to record highs in 2017, achieving $189.6 billion in sales. Elepreneurs LLC provides basic and advanced programs for its new and veteran members who desire to make entrepreneurship their main careers. Thus, Elepreneurs LLC’s mission is elevating entrepreneurship and providing Elepreneurs with the mindset, skill set, knowledge, system, action plan, tools, awareness, motivation and confidence to build a successful business and a better quality of life (http://ibn.fm/FRCO4).

First-rate products and services are vital to the success of both SHRG and its Elepreneurs. As such, SHRG has a growing selection of health and wellness products dedicated to elevating the well-being of all people.

Elepreneurs LLC recently launched its Elevacity Global LLC product. Elevacity Global is a product-sourcing and supply business with a mission of elevating health and happiness by way of patented and powerful nutritional products. The Elevacity brand consists of core products in the nutritional beverage category, including supplements such as XanthoMax(R) and innovative skin care offerings such as Timeless.

A competitive strength of SHRG is its proprietary, patented nutritional products. These products contain scientifically backed ingredients that stimulate what SHRG calls the happiness hormones: dopamine, oxytocin, serotonin and endorphins. SHRG refers to these as D.O.S.E.

Relying on the expert guidance of its proven core leadership team, SHRG is expanding to global markets and plans to market its Elevacity product line in Canada, New Zealand and Australia. With its recent record-breaking increase in sales from the launch of its premier health and wellness products, SHRG offers investors potential ROI from diverse verticals. The company is ideally positioned to capitalize on the forecast growth of the direct-selling industry.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SHRG shareholders have elected John “JT” Thatch, Keith R. Halls and Kip H. Allison to the company’s board
• Thatch is SHRG’s CEO, Halls is Elepreneurs’ president and Allison is Elepreneurs’ CEO
• Shareholders also ratified the appointment of Ankit Consulting Services, CPA, as SHRG’s accounting firm

At its August 29 annual board meeting, Sharing Services Global Corporation (OTCQB: SHRG) shareholders elected previously announced board members John “JT” Thatch, Keith R. Halls and Kip H. Allison. Thatch, SHRG’s CEO, was elected as a board member through the company’s annual meeting in 2022, Allison was elected through the 2021 annual meeting and Halls was elected through the annual meeting of 2020 (http://ibn.fm/xu2S9).

Additionally, shareholders voted to ratify the board’s naming of Ankit Consulting Services Inc., CPA, as the company’s independent, registered public accounting firm for the fiscal year ending April 30, 2020.

In an earlier 10-K SEC filing, SHRG reported record sales of $85.9 million for its fiscal year ended April 30, 2019 (http://ibn.fm/5kZJG). This represents a nine-fold increase, or $77.5 million jump, from the company’s revenues of $8.4 million in FY2018. Sharing Services is focused on continuing its international expansion plans during the remainder of 2019, the filing noted.

“Our 2019 revenues are continued proof that our ‘Blue Ocean Strategy’ is being implemented and accepted in the direct-selling marketplace,” Thatch stated in a news release (http://ibn.fm/aBphU). “We continue at a record-breaking pace as our dedicated and highly talented Elepreneurs continue to execute on the mission to change the direct-selling industry with best-in-class products and services.”

SHRG’s achievements in sales are attracting market attention, in part because of the direct-selling industry’s competitive landscape. Despite contending with leading network marketing companies like Amway Corporation, Avon Products, Herbalife, Mary Kay and NuSkin Enterprises, which “have a longer operating history, higher visibility, name recognition and more financial resources,” SHRG continues to realize impressive financials (http://ibn.fm/WMXOV).

In its 10-K filing, SHRG reported that for its fiscal year ended April 30, 2019, some 97 percent of its consolidated net sales were generated by its Elevate health and wellness product line. Economies of scale and selective price increases helped SHRG grow its consolidated gross profit to $57.1 million, up from $4.4 million for the period from May 5, 2017 (inception), to April 30, 2018. The company’s consolidated gross margin rose to 66.5 percent for the fiscal year ended April 30, 2019, compared to 52.3 percent from the previous year (http://ibn.fm/8rCvR).

Additionally, SHRG reported cumulative $94-plus million sales since the launch of products via its Elepreneurs and Elevacity Global subsidiaries. Thatch noted that Elevacity Global has consistently increased its sales of health and wellness products. Since the product launch in late 2017, SHRG has supported the expansion with several initiatives, including establishing a new corporate headquarters to accommodate growth, bringing in experienced industry talent and pursuing global expansion plans (http://ibn.fm/kzRGp).

SHRG is a Plano, Texas-based diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling by utilizing independent sales contractors. Sharing Services also offers services such as energy, technology and insurance. Its divisions include Elevacity Global LLC and Elepreneur LLC.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• The company believes that its total revenue will more than double in 2020, led by commercialization of its revolutionary CBD oil nanoemulsification system
• PBIO’s BaroShear K45, based on the company’s proprietary Ultra Shear Technology (UST) platform, revolutionizes the manufacture of water-soluble, long-term, stable, highly absorbable, nanoemulsified CBD oil
• The worldwide CBD market is expected to reach $20 billion in sales by 2024, with competition ramping up as CBD manufacturers seek new ways to stand out
• PBIO has announced three pre-sales of its BaroShear K45 nanoemulsification system for making water-soluble CBD Oil
• Progress continues on the build-out of its GMP-compliant manufacturing laboratory to showcase the BaroShear K45 and its industrial scale, high volume UST-based nanoemulsification systems (release date to be determined)

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, expects its total revenues to more than double in 2020 following the successful launch of its revolutionary CBD (cannabidiol) processing system – the BaroShear K45. This novel processing system creates a water-soluble CBD oil that disperses instantly in liquid, providing enhanced quality and bio-absorption (http://ibn.fm/PSUr8).

Development of the BaroShear K45 system began following the company’s in-depth analysis of the CBD market, which showed a common, yet critical production issue facing CBD manufacturers – the poor water solubility of today’s oil-based CBD products means that the beneficial properties of CBD are inadequately available for absorption in the body.

“After much diligence and analysis, we concluded that we have the expertise and experience to successfully address this critical issue,” Richard T. Schumacher, president and CEO of PBIO, stated in an August 2019 shareholder report (http://ibn.fm/Ym0dG). “Consequently, we pulled significant hours away from many of our staff over the past few months and had them focus on the development of an instrument system – based on our patented UST platform – that would increase the water-solubility, and thus the absorption, of CBD Oil. We succeeded; the result of that success is the BaroShear K45 processing system.”

The collective market for CBD sales in the U.S. is expected to exceed $20 billion by 2024, according to a new report from BDS Analytics and Arcview Market Research (http://ibn.fm/RJsFW). The forecast includes products sold through licensed dispensaries and general retail outlets such as grocery stores, mass merchants and pharmacies. Standing out from the crowded field of competitors will be essential for any business pursuing the spotlight in a rapidly expanding CBD marketplace.

“To survive, companies will need to differentiate themselves from the competition by delivering the highest quality products possible,” Schumacher added. “Such products would undoubtedly need to have high water-solubility, absorption, and bioavailability, along with long shelf-life and a minimal amount of added chemicals. This is exactly what we intend to deliver.”

PBIO announced the initial sale of the BaroShear K45 processing system to its first customer, Nano CBD Cosmetics LLC, in an earlier news release (http://ibn.fm/XSn75). Nano CBD Cosmetics founder and CEO Christopher Holden expressed excitement with his company’s purchase.

“We are thrilled to be the first purchaser of the BaroShear K45 system,” Holden stated in the release. “This groundbreaking technology will enable companies producing nano-scale CBD emulsion products to meet the ever-increasing demand for CBD nanoemulsion products. In fact, our own nano-CBD products are currently selling faster than we can produce them. However, with PBIO’s cutting-edge technology, we expect to increase our nano-emulsified, water-soluble CBD production capacity to many multiples of what it is today… and that is huge.”

Following the announcement of its initial pre-sale, PBIO has continued to pre-sell additional, limited quantities of the BaroShear K45. The company recently announced two additional pre-sales of the K45 system (http://ibn.fm/ExADD) – one to NanoPeak Solutions Inc., a private company located in Vancouver, British Columbia, and the second to a private company in Las Vegas, Nevada. This leaves just nine remaining systems available for the PBIO pre-sell program. Units sold over the coming weeks are on track to be delivered and installed in the first half of 2020.

“We believe that such sales will have a significant impact on 2020 total revenue, potentially resulting in more than twice the total revenue of 2019,” Schumacher stated in a news release. “We further believe that revenue from our BaroFold platform contract services will continue to increase, and that the decline in PCT platform instrument sales observed over the past two quarters (caused in part by our focus on the development of the BaroShear K45) will end, and that we will see an increase in PCT product sales over the second half of 2019, and beyond.”

Two short videos released by PBIO (http://ibn.fm/WZy4P and http://ibn.fm/9EqfO), showing how its patented UST platform is able to process CBD plant oil into a water-soluble nanoemulsion, give a quick lesson in PBIO’s proprietary technology.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• ETST is focused on its developing role as an international leader in the CBD space
• The company recently filed a securities registration statement with the SEC
• ETST recently named a pharmaceutical and orthopedic expert as head of its new sales division

Earth Science Tech Inc. (OTCQB: ETST) is an innovative science-based biotechnology company operating in the fields of hemp-derived cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and development (R&D). The company, based in Doral, Florida, recently announced its establishment of a new sales division specifically focusing on CBD products of therapeutic and pharmaceutical grades.

The company’s CBD (cannabidiol) oil is 100 percent natural and organic. In contrast to its competitors, which may use dangerous hemp extraction methods including toxic solvents or high heat, ETST’s CBD-rich hemp does not contain any synthetic cannabinoids and is not an isolate. Through its subsidiaries, Earth Science Tech is focused on developing its role as a world leader in the CBD space.

The impetus behind this new division comes from increased interest in CBD products across multiple medical communities, including medical, holistic and alternative medicine (http://ibn.fm/ugOM9). The division will be headed by Erika Franck, who has been serving as the company’s clinical and therapeutics sales director for several weeks. In her new role, Franck will be working with medical providers, chiropractors, acupuncturists, holistic wellness practitioners and veterinarians, utilizing her years of experience in the medical field to bring the benefits of CBD to a myriad of industries.

Franck’s expertise includes CNS (central nervous system), psychiatry, cardiology, pulmonology, asthmas, allergy and dermatology, which she cultivated through working in the pharmaceuticals and orthopedics industry for over 15 years. During her time in pharmaceuticals, Franck launched two new drugs into the medical market: Lexapro (a type of antidepressant) and Benicar (a drug used to treat high blood pressure).

“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck said in a news release. “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s growth as we achieve this mission.”

ETST president, director, and chairman Nickolas Tabraue announced his excitement at adding Franck’s leadership experience to the division. “She brings a wealth of knowledge and experience to the team that will be invaluable as we pursue opportunities through this exciting new sales channel,” Tabraue added. “We pride ourselves on hiring the very best and brightest, and Erika certainly fits that criteria.”

Recently, ETST filed its Form S-1/A securities registration statement (http://ibn.fm/7ebl1). It was filed with the U.S. Securities and Exchange Commission (SEC) on September 10, 2019. The document details the company’s long-term strategy, partnerships and strategic focus, as well as providing an overview of its subsidiaries.

The company continues to expand its work in the pharmaceutical and medical device sectors through its subsidiaries, which include Nutrition Empire Inc., Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. (CTI), and KannaBidioiD (KBD). ETST also has its Canadian subsidiary, Canna Inno Laboratories Inc.

ETST continues to focus on the CBD market with its broad array of well-branded products and premier distribution. For investors, the company has a strong in-house team and strategic partnerships to foster continued growth. ETST is advancing further projects using its high-grade and inventive products.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST